Barbara Olivero

A real‐life evaluation of two platelet cross‐matching programmes for the treatment of patients refractory to platelet transfusions

Nicoletta Revelli, Maria Antonietta Villa, Barbara Olivero, Susanna Bresciani et autres

BACKGROUND AND OBJECTIVES: Strategies for overcoming alloimmune refractoriness to random donor platelets are based on the use of compatible platelets selected from large panels of HLA-typed donors or cross-matching (XM). The aim of this study was to review the effectiveness of a …

it (code pays fourni par la source)

Use of fresh-frozen plasma in 2012 at the Fondazione Ca' Granda Hospital of Milan: assessment of appropriateness using record linkage techniques applied to data routinely recorded in various hospital information systems.

Monica Lanzoni, Barbara Olivero, Andrea Artoni, Maurizio Marconi et autres

BACKGROUND: The Quality Unit of a research and teaching hospital in Milan assessed the increased clinical use of fresh-frozen plasma in patients treated during 2012 in order to evaluate the appropriateness of this use. MATERIALS AND METHODS: For each patient in the …

it (code pays fourni par la source)

Clinical effectiveness of platelets in additive solution treated with two commercial pathogen‐reduction technologies

Paolo Rebulla, Stefania Vaglio, Francesco Beccaria, Maurizio Bonfichi et autres

BACKGROUND: Two noninferiority, randomized, controlled trials were conducted in parallel comparing the safety and efficacy of platelets treated with Intercept or Mirasol pathogen-reduction technologies versus standard platelets. STUDY DESIGN AND METHODS: The primary endpoint was the percentage of hematology patients who developed …

it (code pays fourni par la source)

PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL)

Marco Ladetto, Chiara Lobetti‐Bodoni, Barbara Mantoan, Andrea Evangelista et autres

Abstract Abstract 787 Background: Many studies support the value of PCR-based MRD detection using the bcl-2-IgH translocation as an outcome predictor in FL but some failed to confirm this observation. Concerns have been raised particularly for programs which are highly Rituximab (Rtx) …

it (code pays fourni par la source)

Unilateral Exophthalmos and Multiple Subcutaneous Nodules As a Result of Extranodal Marginal Zone Lymphoma

Daniele Vincenti, Nicola Orofino, Andrea Ferrario, Maria Goldaniga et autres

it (code pays fourni par la source)

Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B‐cell nonfollicular lymphomas

Andrea Ferrario, Alessandro Pulsoni, Barbara Olivero, Giuseppe Rossi et autres

BACKGROUND: Indolent nonfollicular non-Hodgkin B-cell lymphomas (INFLs) are clonal mature B-cell proliferations for which treatment has not been defined to date. METHODS: In this phase 2 study of patients with advanced INFL, the authors evaluated the efficacy and safety of first-line rituximab, …

it (code pays fourni par la source)

A Retrospective Analysis of Mantle Cell Lymphoma Patients Series Treated Upfront by Sequential High Dose Immunochemotherapy Supported by In Vivo Purged Stem Celle Double Autologous Transplantation: A Monocentric Experience

Andrea Ferrario, Giorgia Saporiti, Nicola Orofino, Francesco Onida et autres

Abstract Abstract 4949 Mantle Cell Lymphoma (MCL) is a rare lymphoma that accounts for 3–10% of all non Hodgkin's Lymphoma in adults. Being associated with rapid progression and high recurrence rate, although some treatment improvements during the last years, it is still …

it (code pays fourni par la source)

Role of positron emission tomography in indolent non Hodgkin lymphomas

Federica Rossi, Ángel Ferrario, Barbara Olivero, Maria Goldaniga et autres

Post-transplant lymphoproliferative disorders in liver and kidney recipients : a single institution experience

Andrea Ferrario, Daniele Vincenti, Francesca Gaia Rossi, Nicola Orofino et autres

Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant

Francesco Spina, Vittorio Montefusco, Claudia Crippa, Annalisa Citro et autres

Evidence of long-term response to lenalidomide in heavily pretreated patients with multiple myeloma is lacking. This study sought to assess whether long-term responders exist, long-term responders' characteristics, and predictive factors of a long-term response. One hundred and four patients with multiple myeloma …

it (code pays fourni par la source)

Indolent B-Cell Lymphomas Treated Upfront with Antiviral Therapy: a Series of 13 Patients

Andrea Ferrario, Alessio Aghemo, Maria Goldaniga, Michele Merli et autres

Abstract Abstract 2876 Background: HCV infection has been demonstrated to be involved in clonal B cell proliferation and in the subsequent development of non-Hodgkin's lymphoma (NHL). The regression of NHL after antiviral treatment is considered an indirect evidence of this pathogenetic relationship. …

it (code pays fourni par la source)

Efficacy and Safety of Once Weekly Bortezomib In Multiple Myeloma Patients

Sara Bringhen, Alessandra Larocca, Davide Rossi, Alessandra Romano et autres

Abstract Abstract 3029 Background. In a recent phase 3 trial, bortezomib–melphalan – prednisone–thalidomide followed by maintenance treatment with bortezomib–thalidomide (VMPT-VT) demonstrated superior efficacy compared with VMP. Peripheral neuropathy (PN) was the most important dose limiting toxicity. To decrease neurologic toxicities, the protocol …

it (code pays fourni par la source)